fracture [he/him]

  • 0 Posts
  • 15 Comments
Joined 1 year ago
cake
Cake day: June 21st, 2023

help-circle
  • beyond the obvious ways this is fucked up, imagining this happening with AI gen text is insane. trying to craft a post to both empathize with another poster, kindly demonstrate flaws in thinking or logic about a point they usually care a lot about, and trying to explain how the different point of view better supports the things they care about it such a monumental effort already that AI just cannot do. no actual persuasion will come out of this (not that a ton happens on the internet to begin with, but even less than that)

    and honestly if you’re firehosing people like that, AI is just going to absolutely drown out any actual communication from happening. at some point, we’ll just have bots going to war for us about our points, and no one will be reading it


  • i would have liked it if this had offered a COVID perspective on communal baths. i’m inclined to think that a hot moist environment is a likely place for it to flourish, and it seems odd to neglect to mention that three years of a pandemic probably had an outsize impact on the number of bathhouses still open in 2022

    obviously we probably don’t have a ton of data on how to circulate air and filter COVID out of bathhouses, but i also bet there’s a way to do it in a relatively energy efficient way

    anyways, it feels like a major spot that’s lacking in an otherwise informative and well thought out read




  • these are not totally serious thoughts, altho they reflect my kind of feelings about it

    but IP should be periodically put to a vote, maybe a year or two after a major release, in which the public decides if they should retain ownership of the IP

    if not? it’s released into public domain. obviously the original company / creator can still do something with it, but others can, as well. but if they do a good job keeping people happy with it, they can keep it

    obviously this has some problems, mostly about constantly polling people and probably only dealing with IP that’s popular enough

    but the idea gives me some deep satisfaction after seeing some companies ruin their IP, and i like the idea of consumers having some power to punish them for being shitty lol


  • it’s an interesting article, but i think the authors are conflating friction for wanting genuine human interaction; its easier than ever for me to make friends because i can instantly connect with and message back and forth, quickly and in real time, over various platforms e.g. discord, the depth of which is only limited by our interactions and how we treat them. forcing us back to sms/email/paper mail doesn’t make our interactions deeper, even though it adds friction. it means we can easily choose what the depth of connection we want is

    that isn’t to say that there aren’t examples where less friction leads to less interaction. dating apps are a great example. but i think the authors are conflating the friction for the interaction. yes, you could add friction that would encourage interaction, but you could also add friction that doesn’t. i think the more salient point would be, encouraging interaction often includes friction, but one shouldn’t shy away from that, as a UI/UX developer

    which, granted, isn’t as catchy of a title. but they could have gone into greater detail for that in the article, too

    regardless of this critique, i enjoyed reading it and the perspective it offered, even if i don’t strictly agree


  • oh okay, sorry, i took away a different impression from your OP talking about how the FDA process is flawed due to appeals being the starting point (which very well may be true) - but including that with this article made it seem like you felt that way about this particular incident (e.g. the link was supporting evidence), not that the commentary on the FDA process was it’s own, unrelated thing

    glad to hear that we’re in agreement about the denial, though

    i can’t really comment on the process, i’ve never taken mdma myself. that said, you say there’s no way you wouldn’t know you’re on it, but there’s a number of substances out there where you’d think that would be the case, but it isn’t (think like, the stereotype of people acting drunk with little / no alcohol, just thinking they had it). also, the dosages may be lower / less obvious, although i have no idea what the dosages used for recreational use vs for therapeutic use are here


  • idk dawg this seems pretty sound according to the article

    The FDA and its advisors identified flaws in the design of the clinical trials, missing data, and a variety of biases in people involved with the trials, including an alleged cult-like support of psychedelics. Lykos is a commercial spinoff of the psychedelic advocacy nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS).

    FDA advisors also noted the public allegations of a sexual assault of a trial participant during a Phase II trial by an unlicensed therapist providing the MDMA-assisted psychotherapy.

    On Saturday, using the existing data and scientific literature to support MDMA therapy got a little more difficult for Lykos. The journal Psychopharmacology posted retraction notices for three studies that involved Phase II clinical data of the therapy. The studies included a 2019 rationale for a Phase III trial design, a 2020 pooled analysis, and a 2020 study on how antidepressant use may affect the response to MDMA therapy.

    The retraction notice cited two reasons for the retractions, including “protocol violations amounting to unethical conduct” at one of the clinical trial sites—a reference to the sexual assault allegations—and undisclosed conflicts of interest by the authors.

    like. these are pretty good reasons for not going ahead. it’s on lykos and the scientists running the trials for not keeping their paperwork straight and, you know, not warning people about the risks of the study

    from an article cited within (https://qz.com/1809184/psychedelic-therapy-has-a-sexual-abuse-problem-3):

    A few years ago, a therapist working in a MAPS MDMA study publicly spoke about his challenges dealing with a patient’s sexuality. Early in his career, Richard Yensen was working with a “lovely young lady who became very sexualized in her relationship around the [MDMA] sessions,” he told an audience at California Institute of Integral Studies in 2016. “It got so intense,” said Yensen, that the chair of his department saw him mid-therapy session and told him to leave the room, warning him to always have another therapist alongside him during sessions. “And thank god, because she became more and more and more activated sexually,” said Yensen. “I don’t think I could have handled it.”

    Not long after, Yensen was accused of sexually assaulting a PTSD patient, Meaghan Buisson, during a MAPS clinical trial on MDMA

    like. even GENEROUSLY assuming that nothing truly unethical happened. this is a huge issue that will only get worse if it’s made publicly available

    i’m not taking a position on whether or not it should be made available as a treatment. i don’t know and i’m not qualified to determine that. but given what’s been said, it feels reasonable to want more data and perhaps go “hey think you could run a trial without getting accused of assaulting people?”






  • thanks for sharing this information with us, i think it’s important to discuss this stuff on the fediverse

    i notice that beehaw doesn’t have a similar clause in its TOS, as far as i can tell. without the expectation of you answering this question, i’m wondering what the difference is between the two such that cohost has such a clause and beehaw doesn’t. maybe it’s because one is run by an individual and one is run by a small company?

    i did a search on cohost itself to see if anyone else talked about this and found this quite extensive thread: https://twitter.com/rahaeli/status/1588769277053739010

    so based on what you’ve said and what’s in that thread, i’m gonna update my post with some qualifications about cohost. thanks for piqing my interest in the TOS